Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFN-10 subcutaneous rizatriptan pharmacokinetics, safety, and tolerability study in healthy adults
NL-OMON42170Active, not recruiting
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of DFN-10 in migraine, migraine with aura and migraine without aura (5 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoints: Pharmacokinetics, safety and tolerability of single-dose subcutaneous DFN-10 and Pharmacokinetic comparison of DFN-10 versus Maxalt. Started Dec 2014; status: active, not recruiting.
02
Drugs
DFN-10
03
Conditions
migrainemigraine with auramigraine without aura
Beyond the preview
Go deeper on NL-OMON42170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42170.